Plenary Session

Latest Episodes:

4.15 #AllCOVID-19: the Tough Questions About Policies Concerning the Delta Variant of COVID-19 Aug 19, 2021

Show notes

Today we're compiling all our recent monologues on COVID-19. That's right -- we're taking a break from #zerocovid to give you an episode that's #allcovid! We cover a whole range of news and opinions covering the Delta variant. We give an evidence-based-medicine doctor's take on the question: Are RCTs necessary in the age of COVID19? We also talk about how the American Academy of Pediatrics (AAP) lost the narrative. We detail how America failed kids because the AAP, CDC, & the teachers unions all hate Trump more than they love kids. We cover vaccine boosters: are they justified? Is there enough evidence? We detail how to run a randomized controlled trial of a policy intervention. And, finally, we confront the New York Times opinion article "Actually, Wearing a Mask Can Help Your Child Learn". We confront the tough questions: Do children really need to see faces? Why do we even have faces? Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

4.14 Evolution of GI Cancer Therapy, Editing JCO, Advice for Clinical Trialists with Dr. Alan Venook Aug 11, 2021

Show notes

Today we interview Dr. Alan Venook of UCSF, a renowned expert in clinical trial design and gastrointestinal malignancies. We talk about the evolution of the treatment for colorectal cancer over the last few decades, starting with 5FU. We also discuss his time working as an editor for the Journal of Clinical Oncology and we talk about his advice for budding clinical trialists. Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

4.13 Lessons from Publishing 300 Peer-Reviewed Papers & What Telemedicine Will Do to Cancer Care Aug 06, 2021

Show notes

We have two short thinkpieces for you. The first is on the lessons that can be learned, or have been learned along the way, from publishing 300 peer-reviewed papers in medical/scientific journals. The second is on the recent publication with Jenny Gill out now in the International Journal of Cancer, titled "After COVID-19, telemedicine may be used in addition to usual care and not in lieu of: Implications for health systems". Telemedicine: doi.org/10.1002/ijc.33752 Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

4.12 Real-World Survival Outcomes for Pertuzumab and T-DM1 with Dr. Josee-Lyne Ethier Aug 03, 2021

Show notes

Today we interview Dr. Josee-Lyne Ethier of Queen's University in Kingston, Ontario, Canada on her new paper "Practice Patterns and Outcomes of Novel Targeted Agents for the Treatment of ERBB2-Positive Metastatic Breast Cancer", out now in JAMA Oncology. We talk about the real-world survival outcomes for pertuzumab and T-DM1, comparing these outcomes to the results of pivotal clinical trials CLEOPATRA and EMILIA. Practice Patterns and Outcomes: doi.org/10.1001/jamaoncol.2021.2140 Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

4.11 CheckMate 274, PARADIGM-HF/Ernesto, POLO, & an AI Approach to Reducing Knee Pain Jul 31, 2021

Show notes

Today's episode is a compilation of a few short monologues. We provide an oncologist's evidence-based medicine perspective on four papers: CheckMate 274, adjuvant nivolumab in urothelial cancer; PARADIGM-HF/Entresto; the POLO trial, olaparib in pancreas cancer; and the paper "An algorithmic approach to reducing unexplained pain disparities in underserved populations". CheckMate 274: doi.org/10.1056/NEJMoa2034442 PARADIGM-HF: doi.org/10.1056/nejmoa1409077 POLO: doi.org/10.1056/NEJMoa1903387 Knee pain: doi.org/10.1038/s41591-020-01192-7 Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

4.10 A Deep Dive into CheckMate 649 with Dr. Jeffrey Bien Jul 28, 2021

Show notes

Today we sit down (in person!) with Dr. Jeff Bien of Stanford University to break down all the details -- from the methods to the statistical analysis to the conclusions -- of the CheckMate 649 trial, which pitted first-line nivolumab plus chemotherapy against chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma. CheckMate 649: doi.org/10.1016/S0140-6736(21)00797-2 Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

4.09 Problems with the VISION Trial & Stool Transplant Plus Nivo for Metastatic Melanoma Jul 23, 2021

Show notes

Today we have two short monologues for you on recent papers. The first, by popular request, is the problems with the VISION trial, which treated metastatic castration-resistant prostate cancer with lutetium-177–PSMA-617 (Lu-177–PSMA-617) radioligand therapy and standard of care. The second is on the paper recently published in Science titled "Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients". Fecal transplant: doi.org/10.1126/science.abb5920 Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

4.08 Implications for the Fate of Accelerated Approval from the ODAC Votes of April 2021 Jul 16, 2021

Show notes

In today's quick episode, we talk about our new paper out now in JAMA Network Open titled "The Oncologic Drugs Advisory Committee Votes of April 2021—Implications for the Fate of Accelerated Approval" ODAC Votes: doi.org/10.1001/jamaoncol.2021.3046 Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

4.07 Questions from a Medical Student with Emma Greenstreet and Dr. Vinay Prasad Jul 09, 2021

Show notes

We have a reverse episode for you today! Emma Greenstreet, a second-year medical student at UCSF, interviews our usual host, Dr. Vinay Prasad on why and how he chose hematology/oncology as a specialty, engaging with criticism, mentorship, medical student rotations, choosing a research project, and urging doctors in academia to aim higher. Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

4.06 CAR-T, Oncology RCTs, Social Media, Myeloma, and Career Decisions with Dr. Rahul Banerjee Jul 08, 2021

Show notes

We sat down in person with Dr. Rahul Banerjee, a BMT/CAR-T fellow at UCSF, to talk about all manner of topics including CAR-T, randomized trials in oncology (and, specifically, Dr. Banerjee's two recent papers out now), social media, treating Multiple Myeloma, and how people make career decisions. What Oncologists Can Learn From COVID-19: doi.org/10.1038/s41571-020-00448-y Are Observational, Real-World Studies Suitable: doi.org/10.1001/jamanetworkopen.2020.12119 Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected